Three Healthcare Stocks Under $30 With Reaffirmed Guidance and Near-Term Catalysts

Analyst

โดย 24/7 Wall St.·Read original

Summary · why it matters

Three healthcare stocks trading under $30—Kenvue, Pfizer, and Viatris—offer value setups heading into the second half of 2026. Kenvue, the consumer health company behind Tylenol and Neutrogena, closed at $19.83 and is being acquired by Kimberly-Clark for $3.50 cash plus 0.14625 Kimberly-Clark shares, with shareholder approval secured and the deal expected to close in the second half of 2026. Pfizer trades at $24.32 with a 7.2% dividend yield and a forward P/E of 8, having reaffirmed full-year 2026 revenue guidance of $59.5 to $62.5 billion and adjusted EPS of $2.80 to $3.00, supported by a pipeline that includes roughly 20 pivotal trial starts this year. Viatris, at $16.70, carries a forward P/E of 7 and has three FDA PDUFA decisions due before year-end 2026, while management reaffirmed 2026 guidance and is executing a restructuring targeting $600 to $700 million in annualized cost savings. Each name carries risks including deal execution, patent cliffs, and generic pricing pressure, but all three have reaffirmed 2026 outlooks and identifiable catalysts.